Literature DB >> 28326864

Role of the Notch signaling in cholangiocarcinoma.

Antonio Cigliano1, Jingxiao Wang2,3, Xin Chen3, Diego F Calvisi1.   

Abstract

INTRODUCTION: Cholangiocarcinoma (CCA) is an emerging cancer entity of the liver, associated with poor outcome and characterized by resistance to conventional chemotherapeutic treatments. In the last decade, many signaling pathways associated with CCA development and progression have been identified and are currently under intense investigation. Cumulating evidence indicates that the Notch cascade, a highly-conserved pathway in most multicellular organisms, is a critical player both in liver malignant transformation and tumor aggressiveness, thus representing a potential therapeutic target in this pernicious disease. Areas covered: In the present review article, we comprehensively summarize and critically discuss the current knowledge on the Notch pathway, its specific and key roles in cholangiocarcinogenesis, the treatment strategies aimed at suppressing this signaling cascade in cancer, and the encouraging results coming from preclinical trials. Expert opinion: The Notch pathway represents a major driver of carcinogenesis and a promising therapeutic target in human CCA. A better understanding of the molecular mechanisms triggered by the Notch pathway as well as its functional crosstalk with other signaling cascade will be highly helpful for the design of innovative therapies against human CCA.

Entities:  

Keywords:  Notch signaling; cholangiocarcinoma; preclinical models; targeted therapies

Mesh:

Substances:

Year:  2017        PMID: 28326864     DOI: 10.1080/14728222.2017.1310842

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  18 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  The cholangiocyte primary cilium in health and disease.

Authors:  Adrian P Mansini; Estanislao Peixoto; Kristen M Thelen; Cesar Gaspari; Sujeong Jin; Sergio A Gradilone
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-06-15       Impact factor: 5.187

Review 3.  Current challenges to underpinning the genetic basis for cholangiocarcinoma.

Authors:  Antonio Cigliano; Xin Chen; Diego F Calvisi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-04-23       Impact factor: 3.869

4.  IFT-A deficiency in juvenile mice impairs biliary development and exacerbates ADPKD liver disease.

Authors:  Wei Wang; Tana S Pottorf; Henry H Wang; Ruochen Dong; Matthew A Kavanaugh; Joseph T Cornelius; Katie L Dennis; Udayan Apte; Michele T Pritchard; Madhulika Sharma; Pamela V Tran
Journal:  J Pathol       Date:  2021-05-21       Impact factor: 7.996

5.  Antitumor activity of Notch‑1 inhibition in human colorectal carcinoma cells.

Authors:  Wangdi Liao; Guohua Li; Yu You; Hongping Wan; Qiong Wu; Chongwen Wang; Nonghua Lv
Journal:  Oncol Rep       Date:  2017-12-29       Impact factor: 3.906

6.  YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice.

Authors:  Xinjun Lu; Baogang Peng; Ge Chen; Mario G Pes; Silvia Ribback; Cindy Ament; Hongwei Xu; Rajesh Pal; Pedro M Rodrigues; Jesus M Banales; Matthias Evert; Diego F Calvisi; Xin Chen; Biao Fan; Jingxiao Wang
Journal:  Am J Pathol       Date:  2021-06-12       Impact factor: 5.770

7.  Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model.

Authors:  Mingjie Dong; Xianqiong Liu; Katja Evert; Kirsten Utpatel; Michele Peters; Shanshan Zhang; Zhong Xu; Li Che; Antonio Cigliano; Silvia Ribback; Frank Dombrowski; Antonio Cossu; John Gordan; Diego F Calvisi; Matthias Evert; Yan Liu; Xin Chen
Journal:  Cell Death Dis       Date:  2018-01-18       Impact factor: 8.469

8.  Differentiation-inducing therapeutic effect of Notch inhibition in reversing malignant transformation of liver normal stem cells via MET.

Authors:  Hao Luo; Wei-Hui Liu; Hong-Yin Liang; Hong-Tao Yan; Ning Lin; Dong-Yu Li; Tao Wang; Li-Jun Tang
Journal:  Oncotarget       Date:  2018-02-05

9.  Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.

Authors:  Serena Mancarella; Grazia Serino; Francesco Dituri; Antonio Cigliano; Silvia Ribback; Jingxiao Wang; Xin Chen; Diego F Calvisi; Gianluigi Giannelli
Journal:  Cell Death Differ       Date:  2020-02-10       Impact factor: 15.828

Review 10.  Targeting cancer stem cells in cholangiocarcinoma (Review).

Authors:  Nicole A Mcgrath; Jianyang Fu; Sophie Z Gu; Changqing Xie
Journal:  Int J Oncol       Date:  2020-05-28       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.